AARTIPHARM

Jan 9 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• AARTI PHARMALABS - ENTERS SHARE SUBSCRIPTION AGREEMENT WITH PRO-ZEAL GREEN POWER

• AARTI PHARMALABS LTD - TO ACQUIRE 26.25% EQUITY IN PRO-ZEAL GREEN POWER

Source text: ID:nBSE8FHX7g

Further company coverage: AARP.NS

(([email protected];;))

** Shares of Aarti Pharmalabs AARP.NS fall 3% to 672 rupees

** The pharma co says Gujarat state's pollution control board ordered closure of operations at Valsad plant due to environmental damage

** AARP's down 1% for the week; had gained 36% in 2024

($1 = 85.7800 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected]))

Aug 5 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• AARTI PHARMALABS LTD JUNE-QUARTER CONSOL NET PROFIT 554.5 MILLION RUPEES

• AARTI PHARMALABS LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.55 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: AARP.NS

(([email protected];))

May 31 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• AARTI PHARMALABS - RECEIVED ORDER FROM POLLUTION BOARD FOR CLOSURE OF MANUFACTURING FACILITIES AT CO'S DOMBIVLI PLANT

• AARTI PHARMALABS LTD - CO WILL SHUT PRODUCTION OPERATION WITH EFFECT FROM MAY 31, 2024

• AARTI PHARMALABS LTD - REASONS FOR CLOSURE - COMPLIANCE WITH MPCB INTERIM DIRECTIONS ON FUEL USAGE

Source text for Eikon: ID:nBSE8bGxly

Further company coverage: AARP.NS

(([email protected];))

May 15 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• AARTI PHARMALABS LTD- COMMERCIALIZATION OF ATALI PROJECT EXPANSION EXPECTED IN Q4FY25

• AARTI PHARMALABS LTD- EXPECT EBITDA GROWTH OF ABOUT 10-12% IN FY25

• AARTI PHARMALABS LTD- AIM TO ACHIEVE LONG-TERM GOAL OF OVER 15% ANNUAL GROWTH IN NEXT 3 YEARS

Source text for Eikon: ID:nBSE6Dv9rD

Further company coverage: AARP.NS

(([email protected];))

** Shares of Aarti Pharmalabs AARP.NS up as much as 11.9% to a record high of 581.95 rupees

** The active pharmaceutical ingredients (API) maker on Monday reported a 52.2% Y/Y jump in its March-qtr consolidated net profit to 652.5 mln rupees ($7.8 mln)

** Revenue from operations rose 4.3% Y/Y

** AARP on track for a third consecutive session of gains, if trends hold

** Stock posts biggest intraday pct gain since April 2023

** More than 3.4 mln shares change hands by 11:03 a.m. IST, 16.3x the 30-day moving avg

** Including session's move, stock is up 14.4% YTD

($1 = 83.5020 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

May 13 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• AARTI PHARMALABS MARCH-QUARTER CONSOL NET PROFIT 652.5 MILLION RUPEES VERSUS PROFIT 428.7 MILLION RUPEES

• AARTI PHARMALABS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 5.06 BILLION RUPEES VERSUS 4.85 BILLION RUPEES

Source text for Eikon: ID:nBSE4zYVm0

Further company coverage: AARP.NS

(([email protected];))

Feb 7 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• DEC-QUARTER CONSOL NET PROFIT 527.6 MILLION RUPEES VERSUS 476.9 MILLION RUPEES YEAR AGO

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.49 BILLION RUPEES VERSUS 4.72 BILLION RUPEES YEAR AGO

Source text for Eikon: ID:nBSE11qXTb

Further company coverage: AARP.NS

(([email protected];))

Nov 7 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• INDIA'S AARTI PHARMALABS SEPT-QUARTER CONSOL NET PROFIT 518 MILLION RUPEES VERSUS PROFIT 510.9 MILLION RUPEES

• AARTI PHARMALABS SEPT-QUARTER CONSOL NET REVENUE FROM OPERATIONS 4.4 BILLION RUPEES VERSUS 5.31 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: AARP.NS

(([email protected];))

June 26 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• AARTI PHARMALABS LTD - EXPECTING EBIDTA GROWTH TO BE ABOUT 12%-17% OVER NEXT 2-3 YEARS

Source text for Eikon: ID:nNSEbpqlWM

Further company coverage: AARP.NS

(([email protected];))

May 12 (Reuters) - Aarti Pharmalabs Ltd AARP.NS:

• MARCH-QUARTER CONSOL NET PROFIT 428.7 MILLION RUPEES VERSUS 488.7 MILLION RUPEES

• MARCH-QUARTER CONSOL NET REVENUE FROM OPERATIONS 4.85 BILLION RUPEES VERSUS 4.60 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: AARP.NS

(([email protected];))